Sight Sciences’ management is scheduled to present on Thursday, February 27, 2025, at 7:15 am PT / 10:15 am ET. Interested parties may access a live and archived webcast of the fireside chat on the ...

Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and ...

Sight Sciences (NASDAQ:SGHT – Get Free Report) had its target price dropped by analysts at Stifel Nicolaus from $6.00 to $5.00 in a research report issued to clients and investors on Thursday,Benzinga ...

In a challenging market environment, Sight Sciences , Inc. (NASDAQ:SGHT) stock has touched a 52-week low, with shares falling to $2.54. With a market capitalization of $130.44 million and an ...

9th Military Vision Symposium on Novel Technology and Vision Restoration hosted by Harvard Medical School Department of Ophthalmology and Mass Eye and Ear, February 27-28, 2025, at the Starr Center ...

Standalone canaloplasty and trabeculotomy can deliver meaningfully reduced IOP in the long term and require fewer topical therapy agents.

Moreover, a recent study has demonstrated the effectiveness of the company's OMNI Surgical System in reducing intraocular pressure in patients with primary open-angle glaucoma. UBS has initiated ...

2025 represents a “foundational building year” in which the company’s key growth driver will shift away from the legacy Omni surgical solution to treat glaucoma and to the TearCare dry eye ...

CHARLESTON, S.C. (WCSC) - Lowcountry glaucoma patients will soon have a new option for safer and more efficient laser eye treatment thanks to doctors at the Medical University of South Carolina.